Cencora Inc.COR
Close of Friday, October 23, 2026 · Cencora Inc. is trading above its Pivot, OnlyAlpha's long-term trend line.
Price
$331.03
vs its Pivot
+4.3%
OnlyAlpha Score
69
Trend
Above its Pivot
Last 12 months. Solid line: price. Dashed green: the Pivot.
Returns
| 1 month | Year to date | 1 year | 3 years / yr | 5 years / yr |
|---|---|---|---|---|
| +6.8% | -1.4% | +0.8% | +21.4% | +24.0% |
Dividend: $2.40 a share over the last 12 months, a 0.73% yield at today's price.
Who runs and owns it
In these funds
Big investors that own it (latest 13F)
| Citadel | 0.2% of holdings |
Suppliers, customers and partners
Sells to COR
| Eli Lilly | significant % of revenue each (XBRL: 16-24% each) |
| AbbVie | substantially all US sales combined; none >43% |
| Amgen | >10% of revenue each; 77% of gross rev combined |
| Gilead Sciences | ~90% of US gross sales combined |
| Walgreens (private) | generic sourcing services (WBAD) |
| Embecta | three largest distributors; ~42% of gross sales combined |
| Amphastar Pharmaceuticals | 22% of net revenues |
| Amneal Pharmaceuticals | top-4 customers; ~71% of net revenue combined |
COR sells to
| Walgreens (private) | ~25% of revenue |
| Cigna Group (Express Scripts/Evernorth) | ~13% of revenue (Evernorth) |
From the companies' own annual reports filed with the SEC.
Healthcare · Drug distributors and pharmacies
Get COR in your free daily emailAfter every close: whether COR is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track COR free → Full Stock check
Track COR free → Full Stock check